A compound of Formula (I), a pharmaceutically acceptable salt, a tautomer, a stereoisomer or a geometric isomer thereof, wherein, ring A is selected from the group consisting of C 3-6 cycloalkyl, phenyl and 5 to 10-membered heteroaryl; n is selected from 0, 1, 2 or 3; R 1 is each independently selected from the group consisting of halo, OH, NH 2 , CN, C 1-3 alkyl, C 1-3 heteroalkyl and phenyl, wherein the C 1-3 alkyl, C 1-3 heteroalkyl or phenyl is each optionally substituted with 1, 2 or 3 Rs; R 2 and R 3 are each independently selected from the group consisting of H, halo, OH, NH 2 , CN, C 1-6 alkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl-(CH 2 ) 1-3 -and phenyl-(CH 2 ) 1-3 -, wherein the C 1-6 alkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl-(CH 2 ) 1-3 - or phenyl-(CH 2 ) 1-3 - is each optionally substituted with 1, 2 or 3 Rs; or R 2 and R 3 together with the carbon atom to which they are attached form a 3 to 6-membered ring; R 4 is selected from the group consisting of C 1-6 alkyl and C 3-6 cycloalkyl-(CH 2 ) 1-3 -, wherein the C 1-6 alkyl or C 3-6 cycloalkyl-(CH 2 ) 1-3 - is each optionally substituted with 1, 2 or 3 Rs; R 5 is selected from the group consisting of H and C 1-3 alkyl optionally substituted with 1, 2 or 3 Rs; each R is independently selected from the group consisting of F, Cl, Br, I, OH, Me, NH 2 , NH(CH 3 ) and N(CH 3 ) 2 ; wherein the prefix "hetero" in the C 1-3 heteroalkyl, C 1-6 heteroalkyl and 5 to 10-membered heteroaryl is each independently selected from the group consisting of -O-, -S-, -NH- and N; and in any one of the above cases, the number of the heteroatom or the group containing the heteroatom is independently selected from 1, 2 or 3. ring A is selected from the group consisting of C 3-6 cycloalkyl, phenyl and 5 to 10-membered heteroaryl; n is selected from 0, 1, 2 or 3; R 1 is each independently selected from the group consisting of halo, OH, NH 2 , CN, C 1-3 alkyl, C 1-3 heteroalkyl and phenyl, wherein the C 1-3 alkyl, C 1-3 heteroalkyl or phenyl is each optionally substituted with 1, 2 or 3 Rs; R 2 and R 3 are each independently selected from the group consisting of H, halo, OH, NH 2 , CN, C 1-6 alkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl-(CH 2 ) 1-3 -and phenyl-(CH 2 ) 1-3 -, wherein the C 1-6 alkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl-(CH 2 ) 1-3 - or phenyl-(CH 2 ) 1-3 - is each optionally substituted with 1, 2 or 3 Rs; or R 2 and R 3 together with the carbon atom to which they are attached form a 3 to 6-membered ring; R 4 is selected from the group consisting of C 1-6 alkyl and C 3-6 cycloalkyl-(CH 2 ) 1-3 -, wherein the C 1-6 alkyl or C 3-6 cycloalkyl-(CH 2 ) 1-3 - is each optionally substituted with 1, 2 or 3 Rs; R 5 is selected from the group consisting of H and C 1-3 alkyl optionally substituted with 1, 2 or 3 Rs; each R is independently selected from the group consisting of F, Cl, Br, I, OH, Me, NH 2 , NH(CH 3 ) and N(CH 3 ) 2 ; wherein the prefix "hetero" in the C 1-3 heteroalkyl, C 1-6 heteroalkyl and 5 to 10-membered heteroaryl is each independently selected from the group consisting of -O-, -S-, -NH- and N; and in any one of the above cases, the number of the heteroatom or the group containing the heteroatom is independently selected from 1, 2 or 3. <EOS>